cancer antigen Articles
-
Constructing Oncolytic Viruses: A Revolutionary Approach in Cancer Therapeutics
The contemporary sphere of oncological therapeutics has witnessed a phenomenal shift in methodology, pivoting from conventional treatment modalities to exploring and utilizing the power of biological entities, notably viruses. Oncolytic virotherapy stands as an avant-garde dissertation in this evolution. It is predicated on the judicious fabrication of Oncolytic Viruses (OVs), biological entities ...
-
Possible treatment of human multiple myeloma found
Multiple myeloma is an essentially incurable plasma cell cancer with a very poor prognosis for patients; however, in a recent study published in Science Translational Medicine entitled "Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the protein CD98 heavy chain," scientists from Osaka University in Japan have discovered the CD98 heavy chain, a common ...
By Profacgen
-
Survivin as a biological biomarker for diagnosis and therapy
Survivin (SVN) is a member of the inhibitor of apoptosis (IAP) protein family that promotes cellular proliferation and inhibits apoptosis. Overexpression of SVN is associated with autoimmune disease, hyperplasia, and tumors and can be used as a biomarker in these diseases. SVN is widely recognized as a tumor-associated antigen (TAA) and has become an important target for cancer diagnosis and ...
-
Antibody-peptide epitope conjugate (APEC), another disguise for ADC
Background Tumor immunotherapies compose immune checkpoint inhibitors, therapeutic antibodies, tumor vaccines, cellular therapies, and so on. However, each has its own set of issues, such as the fact that CAR-T therapy is an individual therapy that is costly; immune checkpoint inhibitors are highly effective, but only in some patients. The researchers expose us to a radically different way of ...
-
Three generations of ADC Nearly a decade of development-PIII
Novel cytotoxic drugs New cytotoxic drugs have been developed to target cancer cells with low antigen expression or resistance to auristatins or maytansinoids. For this purpose, PBD dimers have been developed, which have a molecular structure containing two alkylated imine functional groups capable of forming covalent bonds with DNA.PBD dimers are about 50-100 times more potent than conventional ...
-
The Emergence of a New Force: Circular RNA
Circular RNAs are closed-loop single-stranded RNA (ssRNA) that are structurally specific, and produced by the back-splicing process. CircRNAs can exist independently of proteins and are unaffected by exonucleases, and are widely found in plant and animal cells to regulate gene expression. Circular RNAs were first discovered by Sanger studying virus-like RNAs. And in 1991, Nigro stumbled upon an ...
By CD Genomics
-
The Problem with Gene-Modified Cell Therapy Manufacturing
Gene-modified cell therapies (GMCTs) represent the most effective therapeutic platform for many patients with advanced diseases including relapsed and refractory leukemia, non-Hodgkin lymphoma, and other blood cancers [1]. Specifically, chimeric antigen receptor T cell (CAR-T) therapies targeting CD19 have demonstrated remarkable responses and possibly cures in patients with advanced acute ...
By Indee Labs
-
mRNA Delivery System
RNA is a hydrophilic, negatively charged macromolecule, and its ability to autonomously transmembrane is limited. Therefore, how to efficiently deliver mRNA to the cytoplasm and play a corresponding role is one of the key issues that limit the application of RNA therapy. The wide range of applications of therapeutic mRNA requires efficient and safe delivery methods. An ideal delivery system ...
By BOC Sciences
-
Global ADC Drug Overview
In recent years, antibody-drug conjugates (ADCs) have been widely sought after due to their excellent clinical performance and market returns. ADC drugs are composed of three parts: antibody, effector molecule (Payload, usually cytotoxic agent) and linker. Compared with traditional drugs, ADC drugs have obvious advantages in improving targeting and reducing side effects. 1. Global ADC listing ...
By BOC Sciences
-
ADC Cleavable Linker : Classification and Mechanism of Action
Antibody-drug conjugates (ADCs), as emerging anticancer drugs, can deliver highly cytotoxic molecules directly to cancer cells to kill them. ADC is a monoclonal antibody covalently bound to cytotoxic chemical substances (payload) through linker. ADC linker plays a key role in the therapeutic effect of ADC, and its characteristics greatly affect the therapeutic index, pharmacodynamics and ...
By BOC Sciences
-
Antibody Selection for ADC Drugs
Antibodies are the precise guidance components of ADCs. In theory, molecules that bring effector molecules to the surface of tumor cells can play the role of antibody guidance The choice of antibody for ADC drugs depends on the target of the disease. Targets can be divided into tumor-specific antigens (TSA) and tumor-associated antigens (TAA) according to their expression. Antigens that are only ...
By BOC Sciences
-
Optimization of Three Elements of ADC Drugs
Structurally, an ADC consists of monoclonal antibodies (Antibody) that target specific antigens on tumor surfaces, cytotoxic drugs (drugs) that kill tumor cells, and linkers (Conjugate/ linkers) that conjugate cytotoxic drugs to antibodies. The link between the antibody and linker is controlled by the coupling method, which determines the DAR value of the drug and affects the stability and PK ...
-
Three generations of ADC: Nearly a decade of development-PI
Antibody-drug conjugate (ADC), a compound that connects a cytotoxic small-molecule drug to a monoclonal antibody via a rationally established linker, which selectively delivers an efficient cytotoxic agent into the tumor, has made significant progress in the previous decade. The first ADC drug approved by the US FDA was gemtuzumab ozogamicin (Mylotarg) in 2009. Currently, the FDA has authorized ...
-
Natural killer cell reprogramming with chimeric immune receptors
Abstract Natural killer (NK) cells are emerging as a new tool for cell therapy of cancer. However, some cancer subtypes are relatively resistant to NK cell cytotoxicity. Expression of anti-CD19 chimeric signaling receptors can enhance NK-cell reactivity against CD19+ leukemia and lymphoma cells. Here we describe a method to enforce expression of such receptors in human NK cells relying on ...
By Nkarta, Inc.
-
The nanovaccine technology with huge potentials
Vaccines are an unparalleled medical milestone that has saved countless lives by harnessing the human immune system, according to the history of human development. Vaccine remains the most effective source of defense against the COVID-19 pandemic since 2020. The success of the lipid nanoparticle COVID-19 mRNA vaccine shows that nanotechnology can be used in vaccine development. Compared to ...
-
The ins and outs of TCR-T cell therapy
Adoptive cell transfer (ACT) therapy is one of the most effective therapeutic options for tumor immunotherapy that is currently emerging in clusters. Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) are the main adoptive immunotherapies in recent years. TCR-engineered T cells express tumor antigen-specific receptors with alpha and beta chains generated from high-quality, ...
-
CAR-T Cell Anti-Cancer Therapy Ushered in A Revolutionary Breakthrough!
Chimeric antigen receptor T cells (CAR-T) and T cell antigen receptor chimeric T cells (TCR-T) are currently the "top stream" in adoptive T cell tumor immunotherapy. In particular, CAR-T therapy, which has been approved by the FDA, is rewriting the treatment paradigm of some hematological tumors. However, adoptive T cell therapy remains of little success in solid tumors. The main reason is that ...
-
Antibody-Drug Conjugates For The Treatment of Prostate Cancer
Currently, ADC has played a significant role in the treatment of some malignant tumors, such as trastuzumab in the treatment of breast cancer, but its application in the treatment of prostate cancer (PCa) progress slowly. In recent years, ADC has made rapid progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC). STEAP1, TROP2, PSMA, CD46, and B7-H3 are currently ...
-
Nanobodies Definition, Structure, Advantages and Applications
What is a Nanobody?Nanobodies are the smallest functional single-domain antibodies known to be able to stably bind to antigens, and have unique structural and functional advantages. The molecular weight of nanobodies is only 12-15 kDa, which retains the antigen binding ability of traditional antibodies. However, nanobodies have higher solubility and stability, and have unique advantages in ...
By BOC Sciences
-
Mesothelin: A New Target for Cancer Therapy
Structure and function of mesothelin The MSLN gene is located in chromosome 16p13. It contains 17 exons, with a cDNA length of about 2138bp, has a 1884-bp open reading frame, and encodes the precursor protein of 628 amino acids (69 kDa). This precursor protein can be hydrolyzed by furin protease into two parts: mesothelin in the size of 40 kDa fragments and 31 kDa secreted fragments called ...
By BOC Sciences
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you